ENvue Medical, Inc

As of June 30, 2026, ENvue Medical, Inc. has 8.19M shares outstanding.

As of June 30, 2026, ENvue Medical, Inc. maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.26, indicating elevated leverage, while an interest coverage ratio of -212.56 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. posted a negative return on equity (ROE) of -68.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.87, reflecting losses generated across the asset base. The company generates approximately 92,374.13 in revenue per employee across its workforce of 18.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.01 indicates how many times ENvue Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. recorded an income tax benefit of -308,980.90 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -18.75M and -18.44M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 3, 2026, ENvue Medical, Inc.'s stock has declined approximately 95.74% over the past 52 weeks.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. generated 1.69M in revenue and converted that into -18.44M in net income, yielding earnings per share of -7.09. EBITDA reached -22.14M, while operating income came in at -13.21M.

As of June 30, 2026, ENvue Medical, Inc. holds 948,825.20 in cash and equivalents against 1.15M in total debt, resulting in a net debt position of -3,501.20. Total book value stands at 26.92M, with working capital of -2.18M providing operational flexibility.

ENvue Medical, Inc. produced -10.20M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -83,153.50 in capital expenditures, free cash flow totaled -10.28M - equivalent to -3.96 per share.

Over the twelve months ended June 30, 2026, ENvue Medical, Inc. posted a gross margin of -26.06, reflecting its pricing power and cost economics. The operating margin of -783.59 and net profit margin of -1,093.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 14.04 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

ENvue Medical, Inc.'s most recent stock split took place on September 1, 2026 with a 12:1 split ratio.